In silico comparison of whole pelvis intensity-modulated photon versus proton therapy for the postoperative management of prostate cancer

References

• Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63–89. doi: 10.14740/wjon1191.
   PubMedGoogle Scholar
• American Cancer Society. Cancer Facts and Figures. 2022. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf.
   Google Scholar
• Tendulkar RD, Agrawal S, Gao T, et al. Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol. 2016;34(30):3648–3654. doi: 10.1200/JCO.2016.67.9647.
   PubMed Web of Science ®Google Scholar
• Agrawal V, Ma X, Hu JC, et al. Trends in diagnosis and disparities in initial management of high-risk prostate cancer in the US. JAMA Netw Open. 2020;3(8):e2014674. 08 03 doi: 10.1001/jamanetworkopen.2020.14674.
   PubMed Web of Science ®Google Scholar
• Pollack A, Karrison TG, Balogh AG, et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet. 2022;399(10338):1886–1901. doi: 10.1016/S0140-6736(21)01790-6.
   PubMed Web of Science ®Google Scholar
• Dearnaley D, Griffin CL, Lewis R, et al. Toxicity and patient-reported outcomes of a phase 2 randomized trial of prostate and pelvic lymph node versus prostate only radiotherapy in advanced localised prostate cancer (PIVOTAL). Int J Radiat Oncol Biol Phys. 2019;103(3):605–617. doi: 10.1016/j.ijrobp.2018.10.003.
   PubMed Web of Science ®Google Scholar
• Wilson RR. Radiological use of fast protons. Radiology. 1946;47(5):487–491. doi: 10.1148/47.5.487.
   PubMed Web of Science ®Google Scholar
• Trofimov A, Nguyen PL, Coen JJ, et al. Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys. 2007;69(2):444–453. Oct 01 doi: 10.1016/j.ijrobp.2007.03.018.
   PubMed Web of Science ®Google Scholar
• Vargas C, Fryer A, Mahajan C, et al. Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(3):744–751. doi: 10.1016/j.ijrobp.2007.07.2335.
   PubMed Web of Science ®Google Scholar
• Whitaker TJ, Routman DM, Schultz H, et al. IMPT versus VMAT for pelvic nodal irradiation in prostate cancer: a dosimetric comparison. Int J Part Ther. 2019;5(3):11–23. doi: 10.14338/IJPT-18-00048.1.
   PubMedGoogle Scholar
• Vees H, Dipasquale G, Nouet P, et al. Pelvic lymph node irradiation including pararectal sentinel nodes for prostate cancer patients: treatment optimization comparing intensity modulated X-rays, volumetric modulated arc therapy, and intensity modulated proton therapy. Technol Cancer Res Treat. 2015;14(2):181–189. doi: 10.7785/tcrt.2012.500405.
   PubMed Web of Science ®Google Scholar
• Widesott L, Pierelli A, Fiorino C, et al. Helical tomotherapy vs. intensity-modulated proton therapy for whole pelvis irradiation in high-risk prostate cancer patients: dosimetric, normal tissue complication probability, and generalized equivalent uniform dose analysis. Int J Radiat Oncol Biol Phys. 2011;80(5):1589–1600. doi: 10.1016/j.ijrobp.2010.10.005.
   PubMed Web of Science ®Google Scholar
• Chera BS, Vargas C, Morris CG, et al. Dosimetric study of pelvic proton radiotherapy for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2009;75(4):994–1002. doi: 10.1016/j.ijrobp.2009.01.044.
   PubMed Web of Science ®Google Scholar
• Santos PMG, Barsky AR, Hwang WT, et al. Comparative toxicity outcomes of proton-beam therapy versus intensity-modulated radiotherapy for prostate cancer in the postoperative setting. Cancer. 2019;125(23):4278–4293. doi: 10.1002/cncr.32457.
   PubMed Web of Science ®Google Scholar
• Hall WA, Paulson E, Davis BJ, et al. NRG oncology updated international consensus atlas on pelvic lymph node volumes for intact and postoperative prostate cancer. Int J Radiat Oncol Biol Phys. 2021;109(1):174–185. doi: 10.1016/j.ijrobp.2020.08.034.
   PubMed Web of Science ®Google Scholar
• Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):67–74. doi: 10.1016/j.ijrobp.2007.06.054.
   PubMed Web of Science ®Google Scholar
• Tucker SL, Cheung R, Dong L, et al. Dose-volume response analyses of late rectal bleeding after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2004;59(2):353–365. doi: 10.1016/j.ijrobp.2003.12.033.
   PubMed Web of Science ®Google Scholar
• Huang EH, Pollack A, Levy L, et al. Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2002;54(5):1314–1321. doi: 10.1016/s0360-3016(02)03742-2.
   PubMed Web of Science ®Google Scholar
• Deville C, Jain A, Hwang WT, et al. Initial report of the genitourinary and gastrointestinal toxicity of post-prostatectomy proton therapy for prostate cancer patients undergoing adjuvant or salvage radiotherapy. Acta Oncol. 2018;57(11):1506–1514. doi: 10.1080/0284186X.2018.1487583.
   PubMed Web of Science ®Google Scholar
• Kavanagh BD, Pan CC, Dawson LA, et al. Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S101–S107. doi: 10.1016/j.ijrobp.2009.05.071.
   PubMed Web of Science ®Google Scholar
• Bryant C, Smith TL, Henderson RH, et al. Five-year biochemical results, toxicity, and patient-reported quality of life after delivery of dose-escalated image guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2016;95(1):422–434. doi: 10.1016/j.ijrobp.2016.02.038.
   PubMed Web of Science ®Google Scholar
• Rasmusson E, Nilsson P, Kjellén E, et al. Long-term risk of hip complications after radiation therapy for prostate cancer: a dose-response study. Adv Radiat Oncol. 2021;6(1):100571. doi: 10.1016/j.adro.2020.09.011.
   PubMedGoogle Scholar
• Schad MD, Dutta SW, Muller DM, et al. Radiation-related lymphopenia after pelvic nodal irradiation for prostate cancer. Adv Radiat Oncol. 2019;4(2):323–330. doi: 10.1016/j.adro.2019.01.005.
   PubMedGoogle Scholar
• Mell LK, Kochanski JD, Roeske JC, et al. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66(5):1356–1365. doi: 10.1016/j.ijrobp.2006.03.018.
   PubMed Web of Science ®Google Scholar
• Mell LK, Sirák I, Wei L, et al. Bone marrow-sparing intensity modulated radiation therapy with concurrent cisplatin for stage IB-IVA cervical cancer: an international multicenter phase II clinical trial (INTERTECC-2). Int J Radiat Oncol Biol Phys. 2017;97(3):536–545. doi: 10.1016/j.ijrobp.2016.11.027.
   PubMed Web of Science ®Google Scholar
• Venkatesulu BP, Mallick S, Lin SH, et al. A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors. Crit Rev Oncol Hematol. 2018;123:42–51. doi: 10.1016/j.critrevonc.2018.01.003.
   PubMed Web of Science ®Google Scholar
• Grossman SA, Ellsworth S, Campian J, et al. Survival in patients with severe lymphopenia following treatment with radiation and chemotherapy for newly diagnosed solid tumors. J Natl Compr Canc Netw. 2015;13(10):1225–1231. doi: 10.6004/jnccn.2015.0151.
   PubMed Web of Science ®Google Scholar
• Koerber SA, Katayama S, Sander A, et al. Prostate bed irradiation with alternative radio-oncological approaches (PAROS) – a prospective, multicenter and randomized phase III trial. Radiat Oncol. 2019;14(1):122. doi: 10.1186/s13014-019-1325-x.
   PubMedGoogle Scholar